Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer

PI3Kα-selective inhibitor BYL719 is currently in phase II/III clinical trial for the treatment of breast cancer, but highly variable response has been observed among patients. We sought to discover predictive biomarker for the efficacy of BYL719 by dissecting the proliferative signaling pathway medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yi-chao, Wang, Xiang, Chen, Yi, Chen, Si-meng, Yang, Xin-ying, Sun, Yi-ming, Geng, Mei-yu, Ding, Jian, Meng, Ling-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381259/
https://www.ncbi.nlm.nih.gov/pubmed/28382169
http://dx.doi.org/10.7150/thno.17830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381259/
https://www.ncbi.nlm.nih.gov/pubmed/28382169
http://dx.doi.org/10.7150/thno.17830

Ejemplares similares